- Company
- GSK Korea appoints Maurizio Borgatta as new General Manager
- by Oct 5, 2023 05:27am
- On the 4th, GSK Korea announced it appointed Maurizio Borgatta, former General Manager of GSK Portugal as its new general manager. After joining GSK in 2015, the new GM is known to have successfully launched and sold GSK’s treatments and vaccines in the European region, including Belgium, Spain, Italy, and the UK. Also, he contributed to
- Company
- The reimbursement process for Cosentyx and Taltz
- by Eo, Yun-Ho Oct 5, 2023 05:27am
- The insurance reimbursement registration process for IL-17A inhibitors as first-line treatment for ankylosing spondylitis has been at a standstill for a long time. As a result of the investigation, the two IL-17A inhibitors approved in Korea, Cosentyx of Novartis Korea and Taltz of Lilly Korea completed discussions on expanding the HIRA leve
- Company
- Price cuts for 35 generics suspended…only 0.5% of all
- by Chon, Seung-Hyun Oct 4, 2023 05:35am
- The second case of suspension of execution of price cuts among 7,000 generic drugs emerged on the 5th. The price cuts for 12 generic items from Hutecs Korea will be suspended for 9 months. The number of products for which drug price reductions have been suspended, including the 17 drugs whose price cuts have been temporarily suspended, has i
- Company
- New urothelial cancer drug Padcev attempts reimb in KOR
- by Eo, Yun-Ho Oct 4, 2023 05:35am
- Padcev, the first targeted antibody-drug conjugate (ADC) for urothelial cancer, is attempting reimbursement in Korea. According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for its Padcev (enfortumab vedotin), its antibody-drug conjugate (ADC) that is directed against Nectin-4. The drug is r
- Company
- Padcev can be prescribed at tertiary hospitals in KOR
- by Eo, Yun-Ho Sep 27, 2023 05:44am
- Padcev, the first targeted treatment for metastatic urothelial cancer, can now be prescribed at tertiary hospitals in Korea. According to industry sources, Astellas Pharma Korea’s Padcev (enfortumab vedotin) has passed the review of drug committees (DCs) at all of the ‘Big 5’ tertiary hospitals in Korea - the Samsung Medical Center, Se
- Company
- Daewon’s Pelubi enters Indonesia with a KRW 4 bil deal
- by Chon, Seung-Hyun Sep 26, 2023 05:49am
- On the 25th, Daewon Pharmaceutical announced that its nonsteroidal anti-inflammatory drug, ‘Pelubi CR Tab’ has entered the Indonesian market. Daewon Pharmaceutical signed an exclusive export agreement with its Indonesian partner, PT. Interbat Pharmaceutical Industry, to export its finished Pelubi CR Tablet products to Indonesia. The 5-y
- Company
- Luxturna can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 26, 2023 05:49am
- Luxturna, a one-shot retina treatment, can be prescribed at general hospitals. According to related industries, Luxturna, a treatment for Inherited Retinal Dystrophy, has passed the drug committee of medical institutions such as Seoul National University Hospital. Luxturna is currently in the process of registering for insurance benefits a
- Company
- Roche’s Rozlytrek lands in tertiary hospitals in Korea
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- The tumor-agnostic anticancer drug ‘Rozlytrek’ may now be prescribed in 5 tertiary hospitals in Korea. According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) inhibitor Rozlytrek (entrectinib)’ has passed review of drug committees (DCs) at the Big 5 tertiary hospitals in Korea, - Samsung Medical Center
- Company
- RET-targeted anticancer drugs fail reimb…no promise
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- With RET-targeted anticancer drugs failing to receive reimbursement, patients are now left to wait indefinitely for coverage of their drugs. Lilly Korea's RET inhibitor Retevmo (selpercatinib) failed to be listed for reimbursement last month due to the final breakdown in drug price negotiations with the National Health Insurance Service.
- Company
- Boryung develops 4-drug kanarb combo… increases lineup
- by Chon, Seung-Hyun Sep 22, 2023 05:42am
- On the 20th, Boryung Pharmaceutical announced that the Ministry of Food and Drug Safety has approved the Phase III clinical trial plan (investigational new drug, IND) for ‘BR1018,’ its incrementally modified drug candidate for hypertension and dyslipidemia. BR1018 is a four-drug combination that combined amlodipine, atorvastatin, and e
